Milestone Pharmaceuticals (MIST) to Release Quarterly Earnings on Thursday

Key Points

• Milestone Pharmaceuticals is set to release its Q2 2025 earnings report on August 14th, with analysts predicting a loss of ($0.18) per share.
• The company's previous earnings report showed a larger loss of ($0.31) per share, missing estimates by ($0.12).
• HC Wainwright upgraded Milestone Pharmaceuticals to a "buy" rating with a price target of $5.00, while the average target price among analysts is $7.00.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect Milestone Pharmaceuticals to post earnings of ($0.18) per share for the quarter.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.12). On average, analysts expect Milestone Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Milestone Pharmaceuticals Price Performance

Milestone Pharmaceuticals stock traded down $0.01 during midday trading on Friday, reaching $1.50. 460,202 shares of the stock traded hands, compared to its average volume of 1,768,308. Milestone Pharmaceuticals has a 12 month low of $0.63 and a 12 month high of $2.75. The company has a quick ratio of 4.67, a current ratio of 4.67 and a debt-to-equity ratio of 4.06. The stock's fifty day moving average is $1.72 and its 200-day moving average is $1.61. The stock has a market cap of $80.19 million, a P/E ratio of -1.92 and a beta of 0.52.

Wall Street Analyst Weigh In

Separately, HC Wainwright upgraded Milestone Pharmaceuticals to a "buy" rating and set a $5.00 price target for the company in a research report on Thursday, June 5th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $7.00.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A hedge fund recently raised its stake in Milestone Pharmaceuticals stock. Creative Planning raised its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 74.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,410 shares of the company's stock after buying an additional 10,000 shares during the period. Creative Planning's holdings in Milestone Pharmaceuticals were worth $45,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 86.18% of the company's stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.